Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2010

View Archived Issues

Encouraging phase I data disclosed on phIL-12-005/PPC in recurrent ovarian cancer

Novartis claims new inhibitors of SGLT-1 and SGLT-2

Roche presents new dual 5-HT2A and dopamine D3 receptors modulators

Karo Bio identifies novel estrogen receptor beta ligands

Merck Frosst claims new prostanoid DP2 receptor antagonists

Swedish scientists claim new SSAO inhibitors

ChemoCentryx identifies new CMKLR1 receptor antagonist

Preliminary data disclosed from long-term safety/efficacy phase III trial of LibiGel in HSDD

Almirall presents new DHODH inhibitors suitable for clinical development

Bazedoxifene shows potential as endometriosis therapy in preclinical study

Clinical data disclosed on avosentan in overt diabetic nephropathy

Janssen-Ortho discontinues sale of ceftobiprole in Canada

Clinical data disclosed on lamotrigine in secondary progressive multiple sclerosis

Teva's Copaxone reaches one million patient years of experience in multiple sclerosis

Affinium begins phase I trial of new antistaphylococcal antibiotic AFN-1252

Medinox and Orient Europharma partner for antihypotensive drug NOX-100

Alkermes submits Vivitrol sNDA in U.S. for opioid dependence

Israeli government awards grant to Prolor Biotech for longer-acting human growth hormone

PharmaSurgics' phase II PXL-01 trial extended to Denmark

Arecor and Genzyme join to develop advanced therapeutic protein formulations

RXi and Mirna Therapeutics form microRNA research collaboration

FDA approves Sinapis' methamphetamine IND for stroke

Sanofi Pasteur and U.S. Naval Medicine Center partner to develop travelers' diarrhea vaccine

FDA approves Johnson & Johnson's Pancreaze delayed-release capsules

Aushon launches multiplex biomarker panels to aid measurement of vascular injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...